STAAR Surgical Launches New Visian ICL(TM) Website

STAAR Surgical
Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of
minimally invasive ophthalmic products, today announced that is has
officially launched its new STAAR Visian ICL website at visianinfo
or seebeyondlasik. The site is designed to provide doctors and
consumers with information and other helpful insights that should be useful
in the decision-making process to become users of the ICL.



"The Internet can be a powerful tool to educate both consumers and
doctors and we believe our new website will provide easy access to
compelling data and resources for our Visian ICL," said David Bailey,
President and CEO of STAAR Surgical. "Our website will be a portal through
which users can read about Visian ICL advantages over competing technology,
peruse clinical data supporting the superior visual outcomes, find a doctor
who implants the Visian ICL and review testimonials from patients who have
undergone the procedure.



"We are very proud of the website, which is comprehensive and complete
with educational video and surgical animations of the ICL procedure,"
continued Mr. Bailey. "We are focused on providing the support necessary to
make the Visian ICL a logical choice for both patients and doctors looking
for a new refractive alternative for treating myopia and believe that our
new website will be a key component of this strategy. This is the first
stage in a phased rollout of improvements to all of our websites, including
staar and our international ones, which will focus on improving
website navigation and content."



New Website Features



visianinfo or seebeyondlasik will provide a range of
content that STAAR believes will be helpful to doctors and potential
patients including:


-- What is the Visian ICL?: This portion of the site discusses the
history of eye vision correction, the ICL surgical procedure, the
benefits of the Company's patented Collamer(R) material and the
optimal candidate for the Visian ICL.


-- Advantages: Users can read about the conveniences of the Visian ICL
and get a better understanding of why it might be a good choice for
them.


-- Visian vs. Others: Doctors and patients can assess how the Visian
ICL favorably stacks up against competing technology.


-- Testimonials: In this section users can read about positive first-
hand patient accounts of experiences with the Visian ICL.


-- Clinical Results: This section provides highlight statistics from
the three-year Food and Drug Administration clinical trial and
provides a comparison of the Visian ICL to LASIK for the correction
and reduction of moderate to high myopia.
















-- Locate A Doctor: This section allows potential patients to locate
doctors in their areas who are currently certified to do the Visian
ICL procedure.



About STAAR Surgical



STAAR Surgical is a leader in the development, manufacture and
marketing of minimally invasive ophthalmic products employing proprietary
technologies. STAAR's products are used by ophthalmic surgeons and include
the Visian ICL, a tiny, flexible lens implanted to correct refractive
errors, as well as innovative products designed to improve patient outcomes
for cataracts and glaucoma. STAAR's ICL is approved by the FDA for use in
treating myopia, has received CE Marking and is approved for sale in 43
countries. Approximately 65,000 ICLs have been sold worldwide. More
information is available at staar.



Safe Harbor



All statements in this press release that are not statements of
historical fact are forward-looking statements, including any statements of
the plans, strategies, and objectives of management for future operations,
any statements regarding expectations for success of the ICL or other
products in U.S. or international markets, any statements concerning
proposed new products and government approval of new products, services or
developments, statements of expectations regarding pending transactions,
any statements regarding future economic conditions or performance,
statements of belief and any statements of assumptions underlying any of
the foregoing. These statements are based on expectations and assumptions
as of the date of this press release and are subject to numerous risks and
uncertainties, which could cause actual results to differ materially from
those described in the forward-looking statements. The risks and
uncertainties include our limited capital resources and limited access to
financing, the challenge of adapting our largely independent marketing
model to the challenges of the refractive market, our ability to overcome
negative publicity resulting from warning letters and other correspondence
from the FDA Office of Compliance, the willingness of surgeons and patients
to adopt a new product and procedure, and our ability to successfully
launch and market the ICL in the U.S. while overcoming the foregoing
challenges. Our ability to capitalize on the opportunity presented by the
U.S. ICL approval depends on our overall financial condition, which can be
adversely affected by general economic conditions, and other factors beyond
our control, including those detailed from time to time in our reports
filed with the Securities and Exchange Commission. STAAR assumes no
obligation to update these forward-looking statements to reflect future
events or actual outcomes and does not intend to do so.


STAAR Surgical Company

seebeyondlasik/